Charles Schwab Investment Management Inc Larimar Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 111,400 shares of LRMR stock, worth $433,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111,400
Previous 100,457
10.89%
Holding current value
$433,346
Previous $215,000
49.3%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LRMR
# of Institutions
130Shares Held
66.9MCall Options Held
4.83MPut Options Held
83.7K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$82.6 Million1.41% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$23.5 Million0.38% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$19.2 Million7.71% of portfolio
-
Opaleye Management Inc. Boston, MA4.11MShares$16 Million2.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.66MShares$14.2 Million0.01% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $168M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...